Open AccessChronic Myeloid Leukemia in 2007
Author(s) -
Jolynn Sessions
Publication year - 2007
Publication title -
journal of managed care pharmacy
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1944-706X
pISSN - 1083-4087
DOI - 10.18553/jmcp.2007.13.s8-a.4
Subject(s) - medicine , philadelphia chromosome , myeloid leukemia , chromosomal translocation , cancer research , abl , breakpoint cluster region , disease , cancer , tyrosine kinase , leukemia , myeloid , immunology , oncology , biology , gene , genetics , receptor
Chronic myeloid leukemia (CML) is a potentially fatal stem cell cancer that comprises approximately 14% of all leukemias. Although it is estimated that 4,600 people will be diagnosed with CML in the United States in 2007, only 12% of those individuals will die from the disease. That low mortality rate is due to the availability and efficacy of the new kinase inhibitors that target the BCR-ABL oncogene and other targets to hold disease progression in check.